300086 康芝药业
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)-3.710-22.840-17.514-1.035-13.303
总资产报酬率 ROA (%)-1.871-12.217-10.403-0.616-7.903
投入资产回报率 ROIC (%)-2.387-14.815-11.989-0.700-8.946

边际利润分析
销售毛利率 (%)54.73054.20155.04357.25550.796
营业利润率 (%)-19.087-55.202-45.682-1.193-39.834
息税前利润/营业总收入 (%)-14.089-51.830-43.3611.854-36.693
净利润/营业总收入 (%)-23.145-50.208-47.637-2.902-36.949

收益指标分析
经营活动净收益/利润总额(%)143.89771.22571.6088.55669.002
价值变动净收益/利润总额(%)0.00013.7170.647118.8498.689
营业外收支净额/利润总额(%)-0.0190.8344.29415.7533.661

偿债能力分析
流动比率 (X)0.4550.5220.8501.5121.329
速动比率 (X)0.1580.2470.4910.8930.991
资产负债率 (%)48.14148.56442.27636.83040.768
带息债务/全部投入资本 (%)27.70828.47028.34024.88130.931
股东权益/带息债务 (%)233.141225.108231.128284.242209.659
股东权益/负债合计 (%)105.208103.440133.500167.300141.076
利息保障倍数 (X)-2.821-13.511-9.9200.567-7.883

营运能力分析
应收账款周转天数 (天)41.25140.51678.21745.68874.092
存货周转天数 (天)451.546292.959361.355248.551251.465